Profile data is unavailable for this security.
About the company
SKAN Group AG, former BV Holding AG, is a Switzerland-based holding company of an equity investment group, engaged in the participation in enterprises in Switzerland. It concentrates on companies from the industry, micro and medical technology, processing and material technology, information technology and related services. Target enterprises are those being in special situations, such as management buy-out and buy-in, changes in shareholders’ structure, succession financing, as well as coming through growth or expansion phase. The Company acts as an entrepreneurial partner in the long term. Operational activities are delegated to the independent advisor BV Partners AG. BV Holding AG and BV Partners AG form the BVgroup. As of December 31, 2011, its investment portfolio included nine companies: Covalys BioSciences AG, E2E Technologies Ltd., Lonstroff Holding AG, Piexon AG, POLYDATA AG, SKAN Holding AG, Sphinx Werkzeuge AG, Ypsomed Holding AG and Ziemer Group AG.
- Revenue in CHF (TTM)320.02m
- Net income in CHF26.31m
- Incorporated2001
- Employees1.39k
- LocationSKAN Group AGKreuzstrasse 5ALLSCHWIL 4123SwitzerlandCHE
- Phone+41 432683232
- Fax+41 313801859
- Websitehttps://skan.com/de/home/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arjo AB (publ) | 951.24m | 44.39m | 1.01bn | 6.71k | 24.36 | 1.56 | 7.60 | 1.06 | 1.90 | 1.90 | 40.76 | 29.72 | 0.6911 | 4.15 | 6.31 | 1,632,980.00 | 3.21 | 3.55 | 4.44 | 5.55 | 43.43 | 44.01 | 4.64 | 5.41 | 0.6913 | 4.14 | 0.4024 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| Medartis Holding AG | 212.01m | 619.00k | 1.04bn | 829.00 | 1,567.62 | 3.71 | 48.05 | 4.90 | 0.0488 | 0.0488 | 17.33 | 20.63 | 0.6259 | 0.643 | 5.27 | 255,737.00 | 0.183 | 0.1919 | 0.2095 | 0.2153 | 79.04 | 82.33 | 0.2924 | 0.3542 | 1.59 | 1.46 | 0.1655 | 0.00 | 15.96 | 11.81 | 110.70 | -31.82 | 5.37 | -- |
| Oxford Nanopore Technologies PLC | 195.03m | -177.60m | 1.06bn | 1.24k | -- | 1.43 | -- | 5.46 | -0.1851 | -0.1851 | 0.2035 | 0.7493 | 0.212 | 0.8369 | 2.73 | 137,050.10 | -19.30 | -21.12 | -21.93 | -24.67 | 53.33 | 53.90 | -91.06 | -81.85 | 3.87 | -- | 0.0608 | -- | -14.57 | 39.15 | -69.74 | -- | 8.92 | -- |
| GVS SpA | 415.39m | 20.09m | 1.13bn | 4.39k | 58.40 | 3.34 | 17.74 | 2.73 | 0.1135 | 0.1135 | 2.38 | 1.99 | 0.4201 | 1.95 | 6.20 | 96,823.30 | 2.03 | 7.35 | 2.50 | 10.82 | 53.92 | 58.74 | 4.84 | 12.44 | 1.19 | 3.87 | 0.5709 | -- | 9.58 | 15.25 | -43.37 | -9.97 | 16.08 | -- |
| Xvivo Perfusion AB | 55.09m | 8.61m | 1.19bn | 148.00 | 132.65 | 6.92 | 84.07 | 21.56 | 3.32 | 3.32 | 21.18 | 63.59 | 0.322 | 1.28 | 4.27 | 4,018,431.00 | 5.03 | 1.24 | 5.49 | 1.33 | 73.94 | 73.14 | 15.62 | 4.76 | 3.40 | -- | 0.0152 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| Biotage AB | 169.75m | 20.22m | 1.27bn | 669.00 | 61.58 | 3.81 | 36.81 | 7.49 | 3.01 | 3.01 | 25.57 | 48.61 | 0.5276 | 2.01 | 7.78 | 2,939,169.00 | 6.29 | 10.74 | 7.33 | 12.77 | 62.19 | 61.34 | 11.91 | 15.77 | 1.52 | 8.95 | 0.062 | 40.11 | 18.90 | 15.37 | -8.21 | 7.97 | 14.05 | 1.30 |
| Embla Medical hf | 725.53m | 51.35m | 1.59bn | 4.00k | 30.80 | 2.40 | 16.26 | 2.19 | 0.9174 | 0.9174 | 12.95 | 11.77 | 0.5582 | 2.20 | 6.60 | 1,382,694.00 | 3.96 | 4.06 | 4.68 | 4.76 | 61.41 | 62.47 | 7.09 | 6.91 | 1.07 | 5.81 | 0.4325 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| SKAN Group AG | 320.02m | 26.31m | 1.81bn | 1.39k | 69.02 | 10.69 | 44.92 | 5.66 | 1.17 | 1.17 | 14.23 | 7.53 | 0.8402 | 0.7026 | 12.19 | 230,562.00 | 7.32 | 7.56 | 15.16 | 14.95 | 75.17 | 73.24 | 8.72 | 9.63 | 0.781 | 7.61 | 0.0355 | 24.09 | 15.55 | 118.77 | 38.59 | 35.49 | -- | -- |
| Medacta Group SA | 499.42m | 46.31m | 2.45bn | 1.73k | 52.96 | 7.58 | 23.73 | 4.91 | 2.32 | 2.32 | 24.98 | 16.19 | 0.7979 | 0.8708 | 5.92 | 288,679.40 | 7.40 | 7.89 | 9.09 | 10.57 | 68.10 | 70.43 | 9.27 | 10.09 | 0.9004 | 4.80 | 0.3817 | 17.01 | 16.85 | 13.38 | 2.41 | 0.6937 | 8.32 | -- |
| Holder | Shares | % Held |
|---|---|---|
| J. Safra Sarasin Investmentfonds AGas of 20 Nov 2023 | 820.00k | 3.65% |
| VV Verm�gensverwaltung AGas of 29 Feb 2024 | 785.00k | 3.49% |
| Z�rcher Kantonalbank (Investment Management)as of 28 Mar 2024 | 489.12k | 2.18% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 478.79k | 2.13% |
| Pictet Asset Management SAas of 31 Jan 2024 | 446.63k | 1.99% |
| The Vanguard Group, Inc.as of 09 May 2024 | 399.04k | 1.78% |
| Threadneedle Asset Management Ltd.as of 29 Feb 2024 | 395.88k | 1.76% |
| Vontobel Asset Management AGas of 30 Apr 2024 | 330.16k | 1.47% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 272.46k | 1.21% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 262.81k | 1.17% |
